An interventional study of Peer support in Multiple Sclerosis, Relapsing-remitting, sponsored by Nantes University Hospital. Active, not recruiting at 1 site in France. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by Nantes University Hospital · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France — 9 open to participants now, 14 under way, 7 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · France.
Among the 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France, this one is the 52nd largest by planned enrollment of the 70 interventional ones that give a count, is one of 2 that started in 2023, is one of 16 with no phase, reaches primary completion later than 3 of the 13 other live ones, and was the 71st registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →9 of the 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France are open now. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 40+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18–55
Rennes University Hospital · Sites in France
Ages 18–55
Centre d'Investigation Clinique et Technologique 805 · Sites in France
Ages 18–55 · Healthy volunteers
University Hospital, Strasbourg, France · Sites in France
Ages 18–55 · Men only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 95 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 154 across the 70 interventional studies, 499 across the 12 observational. Of the 65 that completed or were terminated, 28 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 82 have an industry lead sponsor. The 10 most frequent:
Nantes University Hospital is the lead sponsor of 839 studies on the registry; 189 are open to participants now.
Nantes University Hospital has 4 studies filed under Multiple Sclerosis, Relapsing-Remitting — fewer than ten, so there is no comparison to draw.
6 of the studies in Multiple Sclerosis, Relapsing-Remitting with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06663189Phase 3University Hospital, Strasbourg, FranceDisease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis) | 2027-01 |
| NCT06700343Phase 3AmgenComparison Between ABP 692 and Ocrevus® (Ocrelizumab) | 2027-04-19 |
| NCT03958877Phase 3BiogenA Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis | 2027-05-20 |
| NCT05519553Nantes University HospitalPeer Support Impact on Therapeutic Adherence in Patients With Multiple Sclerosis | 2026-12-01 |
| NCT06330077Assistance Publique - Hôpitaux de ParisIfenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A mixed methods randomized controlled trial pilot study to assess peer support impact on relapsing-remitting multiple sclerosis patients' therapeutic adherence.
Multiple sclerosis (MS) is a debilitating and incurable chronic disease. Patients might benefit from peer support provided by patients entitled to give advice on daily life management with MS. Studies have shown that peer support can enhance chronic patients' quality of life in Psychiatry and Oncology.
This pilot study aims at assessing the impact of peer support on therapeutic adherence and quality of life in patients with MS, but also to appraise the project feasibility and acceptability among the healthcare team, with large-scale implementation in mind.
This mixed methods pilot study consists in a monocentric open-label randomized controlled trial. It is located in Nantes, France, and aims to recruit 60 patients with relapsing-remitting MS undergoing drug therapy from the Nantes University Hospital Neurology Department. Patients will be randomized 1:1 to receive either usual care only or usual care combined with peer support (3 individual sessions at 1, 3 and 5 months with a peer support specialist).
Primary outcome is enhanced therapeutic adherence 6 months after baseline, secondary outcomes include therapeutic compliance, quality of life, anxiety and depression, social support. All dimensions will be assessed using validated health questionnaires at baseline and at 6 months.
Interventions acceptability and feasibility will be evaluated using qualitative methods: undirected interviews with patients from the intervention group and 2 focus-groups, one with the peer support specialists and the other with the healthcare team.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
30 MS (Multiple sclerosis, relapsing-remitting) patients
Other: Peer support
30 MS (Multiple sclerosis, relapsing-remitting) patients
: 1 hour individual session with a peer support specialist at 1, 3 and 5 months after baseline
Also known as: non applicable
Therapeutic adherence
Description : score difference at baseline and 6 months of the " Necessity " and " Concerns " subscales of BMQ-Specific (Beliefs about medicines questionnaire) compared between control and intervention groups. A score, between 5 and 25, is calculated for each subscale by making a sum of the answers. Next, score difference between Necessity and Concerns (NCF) is calculated. NCF varies between -20 and +20. Value above 0 means that perceived treatment necessity exceeds treatment associated concerns. The more NCF comes close to +20, the better is the treatment risk/benefit balance.
Time frame: 6 months
Therapeutic compliance
score difference at baseline and 6 months of MARS (Medication Adherence Rating Scale) questionnaire compared between control and intervention groups. A final score, between 5 and 25, is calculated by making a sum of the answers. If final score is 21 or above, or if every item is scored at least 4 points, the patient is deemed compliant.
Time frame: 6 months
Participants' quality of life
score difference at baseline and 6 months of MusiQoL-MCAT (Multidimensional Computerized Adaptive Short-Form Quality of Life Questionnaire Developed and Validated for Multiple Sclerosis) compared between control and intervention groups. The score on each dimension is obtained by computing the mean of the item scores for that dimension. All dimension scores are linearly transformed to a 0 to 100 scale. A global index score is computed as the mean of the dimension scores. Higher scores indicate a higher level of quality of life.
Time frame: 6 months
Emotional wellbeing
score difference at baseline and 6 months of HAD (Hospital Anxiety and Depression) questionnaire compared between control and intervention groups. A final score, between 0 and 21, is calculated by making a sum of the answers for each subscale. A subscale score \>8 denotes anxiety or depression. The higher the score is, the worse the severity of depression or anxiety symptoms.
Time frame: 6 months
Social support
score difference at baseline and 6 months of SSQ6 (Social Support Questionnaire) compared between control and intervention groups. Two scores are calculated by making a sum of the answers in each dimension: N score (availability) ranges from 0 to 54 and S score (satisfaction) ranges from 6 to 36. Higher scores indicate a higher level of support availability or satisfaction.
Time frame: 6 months
Plan to share: No — non applicable
Started May 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.
Of 79 non-industry interventional studies with no phase under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 47. This study's planned 42 months is above that.
Counting every sponsor, half of 81 studies reached it within 29 months; a quarter within 15 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Multiple Sclerosis, Relapsing-Remitting →